StockNews.AI
GERN
StockNews.AI
158 days

GERN Investors Have Opportunity to Lead Geron Corporation Securities Fraud Lawsuit

1. Rosen Law Firm filed a class action for GERN securities purchasers. 2. Investors may receive compensation for misleading statements during a defined Class Period. 3. Misstatements about Rytelo's market penetration impacted investor sentiment and recovery potential. 4. Investors encouraged to select qualified counsel for class action representation. 5. No class has been certified; participation in the lawsuit is optional.

6m saved
Insight
Article

FAQ

Why Bearish?

The class action lawsuit indicates significant shareholder dissatisfaction due to misleading claims, historically leading to price declines in similar cases. Examples include similar legal challenges faced by stock companies which saw stock prices drop upon announcements.

How important is it?

The filing of a class action lawsuit against GERN is a significant legal event. Investor sentiment and stock prices are likely to be heavily influenced by litigation outcomes and associated negativity.

Why Short Term?

The immediate impact is likely as investor sentiment erodes. Historical trends show price reactions correlate swiftly with legal news.

Related Companies

Ryder System Inc (R), Gilead Sciences Inc (GILD)
NEW YORK, March 14, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action on behalf of purchasers of securities of Geron Corporation (NASDAQ: GERN) between June 7, 2024 and February 25, 2025, both dates inclusive (the "Class Period"). If you wish to serve as lead plaintiff, you must move the Court no later than May 12, 2025. So what: If you purchased Geron securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next: To join the Geron class action, go to https://rosenlegal.com/submit-form/?case_id=36747 or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 12, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Details of the case: According to the lawsuit, defendants made false and/or misleading statements during the Class Period. Specifically, defendants created the false impression that they possessed reliable information pertaining to the Geron's projected revenue outlook and anticipated growth while also minimizing risk from seasonality and macroeconomic fluctuations. In truth, Geron's optimistic reports of Rytelo's (a telomerase inhibitor, imetelstat, which is designed to reduce the proliferation of malignant cells to permit the production of new healthy cells) launch success and potential growth fell short of reality; the impacts of seasonality, existing competition, and the burden of continued monitoring played a much more significant role in patient starts than Defendants had implied. Moreover, Rytelo lacked the necessary awareness to penetrate the market, resulting in an inability for Geron to capitalize on the purportedly significant unmet need for the drug, particularly among first-line patients and those outside the academic setting.When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Geron class action, go to https://rosenlegal.com/submit-form/?case_id=36747 or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/. Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq.Phillip Kim, Esq.The Rosen Law Firm, P.A.275 Madison Avenue, 40th FloorNew York, NY 10016Tel: (212) 686-1060Toll Free: (866) 767-3653Fax: (212) 202-3827[email protected]www.rosenlegal.com SOURCE THE ROSEN LAW FIRM, P. A.

Related News